Steven D. Gore, MD

Director of Hematologic Malignancies

Physician Biography

Dr. Gore came to Yale in November 2013 following 23 years on the faculty at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland. Dr. Gore is an international authority on myelodysplastic syndromes (MDS) and other forms of leukemia. He is particularly known for his novel clinical and translational trials in MDS and leukemia, using drugs which target epigenetic abnormalities in leukemia cells. He is a leader in the leukemia effort of the Eastern Cooperative Oncology Group and is a member of the MDS committee of the National Cancer Care Network.

Clinical Interests

  • Hematology
  • Medical Oncology

Patient Care

Accepts new patients? Yes
Patient Type: Adult
Referrals: From patients or physicians

Patient Care Organizations

Cancer Center, Yale: Hematology Program


Yale Medical Group

Clinical Trials

Conditions Study Title
Myeloid and Monocytic Leukemia A Randomized Phase III Study of Standard Cytarabine Plus Daunomycin (7+3) Therapy versus Idarubicin with High Dose Cytarabine (IA) with or without Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Leukemia, not otherwise specified, Leukemia, other, Myeloid and Monocytic Leukemia A Phase 1 Study of Ipilimumab in relapsed and refractory high risk myelodysplastic syndrome and acute myeloid leukemia with minimal residual disease
Myeloid and Monocytic Leukemia A Phase 3 Open-Label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects with FLT3-ITD Positive Acute Myeloid Leukemia (AML) Refractory To or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation
Myeloid and Monocytic Leukemia A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory AML Who Are Ineligible for Intensive Chemotherapy and/or Transplantation
Leukemia, other A Randomized Phase III Study of Bendamustine Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone in Untreated Older Patients (≥65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Lymphoid Leukemia E1912: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
Myeloid and Monocytic Leukemia E2905: Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia
Leukemia, other (E1910) A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-negative B lineage Acute Lymphoblastic Leukemia in Adults
Unknown Sites Specimen Repository for Hematologic Diseases

Edit this profile

Contact Info

Steven D. Gore, MD
Patient Care Location
Yale Cancer Center-YNHHYale-New Haven Hospital
20 York Street, Ste 7th Floor

New Haven, CT 06510
Mailing Address
25 York Street
PO Box 208028

New Haven, CT 06520-8028

Curriculum Vitae